Volumetric and MGMT parameters in glioblastoma patients: Survival analysis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Iliadis, Georgios ^a,b   Kotoula, Vassiliki ^c   Chatzisotiriou, Athanasios ^d   Televantou, Despina ^c   Eleftheraki, Anastasia G ^e   Lambaki, Sofia ^c   Misailidou, Despina ^a   Selviaridis, Panagiotis ^c   Fountzilas, George ^c  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^b INTERBALKAN MEDICAL CENTER   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d St Luke's Hospital   (Greece)

^e Hellenic Cooperative Oncology Group   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLTRANSFERASE; O 6 METHYLGUANINE METHYLTRANSFERASE; RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT THERAPY; ADULT; AGE; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER GROWTH; CHEMORADIOTHERAPY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; GENDER; GENE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; O 6 METHYLGUANINE METHYLTRANSFERASE GENE; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; THREE DIMENSIONAL IMAGING; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR NECROSIS; TUMOR VOLUME; BRAIN TUMOR; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METHODOLOGY; METHYLATION; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; SURVIVAL;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS;

EID: 84855245306     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-3     Document Type: Article

References (66)

1. Welsh J, Sanan A, Gabayan AJ, Green SB, Lustig R, Burri S, Kwong E, Stea B. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys 2007, 68(1):159-65. Epub 2007 Feb 27, 10.1016/j.ijrobp.2006.11.053, 17331666.
2. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot MC, Shenouda G. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 2009, 73(2):473-8. Epub 2008 Jun 12, 10.1016/j.ijrobp.2008.04.030, 18554821.
3. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004, 60(3):853-60. 10.1016/j.ijrobp.2004.04.011, 15465203.
4. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 2006, 65(5):1422-8. Epub 2006 Jun 5, 10.1016/j.ijrobp.2006.02.042, 16750317.
5. Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J, Pintilie M, Bernstein M. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998, 41(5):1005-11. 10.1016/S0360-3016(98)00159-X, 9719109.
6. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome. Strahlenther Onkol 2004, 180(7):401-7. Review.
7. Grabenbauer GG, Gerber KD, Ganslandt O, Richter A, Klautke G, Birkmann J, Meyer M. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009, 75(1):164-9. 10.1016/j.ijrobp.2009.04.015, 19695435.
8. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK, . Radiation Therapy Oncology Group Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 2006, 66(3):818-24. Epub 2006 Aug 2, 10.1016/j.ijrobp.2006.05.021, 16887285, Radiation Therapy Oncology Group.
9. Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A, Ciuleanou E, Ghilezan N, Zamboglou N, Dimitriadis A, Sofroniadis I, Fountzilas G. Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys 2004, 59(4):1018-26. 10.1016/j.ijrobp.2004.01.021, 15234035.
10. Kurek R, Kalogera-Fountzila A, Muskalla K, Dafni U, Schnabel T, Kober B, Roddiger S, Martin T, Fountzilas G, Zamboglou N. Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer. Strahlenther Onkol 2003, 179(5):292-7. 10.1007/s00066-003-1017-0, 12740655.
11. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J, Wazer DE. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 1995, 32(3):635-41. 10.1016/0360-3016(95)00031-S, 7790249.
12. Rudat V, Dietz A, Schramm O, Conradt C, Maier H, Flentje M, Wannenmacher M. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 1999, 53(2):119-25. 10.1016/S0167-8140(99)00119-X, 10665788.
13. Andreopoulou E, Andreopoulos D, Adamidis K, Fountzila-Kalogera A, Fountzilas G, Dimopoulos MA, Aravantinos G, Zamboglou N, Baltas D, Pavlidis N. Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res 2002, 22(3):1903-8.
14. Burghardt E, Baltzer J, Tulusan AH, Haas J. Results of surgical treatment of 1028 cervical cancers studied with volumetry. Cancer 1992, 70(3):648-55. 10.1002/1097-0142(19920801)70:3<648::AID-CNCR2820700318>3.0.CO;2-R, 1623479.
15. Kikuchi S, Sakuramoto S, Kobayashi N, Shimao H, Sakakibara Y, Sato K, Kakita A. Tumor volumetry: proposal of a new concept to predict lymph node metastasis in early gastric cancer. Anticancer Res 2000, 20(5C):3669-74.
16. Stupp R, Roila F, . ESMO Guidelines Working Group Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):126-8. Review, ESMO Guidelines Working Group.
17. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343(19):1350-4. Erratum in: N Engl J Med 2000 Dec 7;343(23):1740, 10.1056/NEJM200011093431901, 11070098.
18. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, . European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-66. Epub 2009 Mar 9, 10.1016/S1470-2045(09)70025-7, 19269895, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.
19. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008, 9(1):29-38. Epub 2007 Dec 21, 10.1016/S1470-2045(07)70384-4, 18082451.
20. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME. MGMT promoter methylation in malignant gliomas: ready for personalized medicine. Nat Rev Neurol 2010, 6(1):39-51. Epub 2009 Dec 8. Review, 10.1038/nrneurol.2009.197, 19997073.
21. Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005, 11(14):5167-74. 10.1158/1078-0432.CCR-05-0230, 16033832.
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, , . European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-96. 10.1056/NEJMoa043330, 15758009, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group.
23. Iliadis G, Selviaridis P, Kalogera-Fountzila A, Fragkoulidi A, Baltas D, Tselis N, Chatzisotiriou A, Misailidou D, Zamboglou N, Fountzilas G. The importance of tumor volume in the prognosis of patients with glioblastoma: Comparison of computerized volumetry and geometrical models. Strahlenther Onkol 2009, 185(11):743-50. Epub 2009 Nov 10, 10.1007/s00066-009-2015-7, 19899008.
24. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of malignant glioma. J Clin Oncol 1990, 8:1277-80.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-8. 10.1006/meth.2001.1262, 11846609.
26. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 2008, 115(2):249-59. Epub 2007 Oct 27, 10.1007/s00401-007-0310-x, 17965865.
27. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, Wesseling P. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 2007, 87(10):1055-65. Epub 2007 Aug 13, 10.1038/labinvest.3700664, 17700563.
28. Nieder C, Adam M, Grosu AL. Combined modality treatment of glioblastoma multiforme: the role of temozolomide. Rev Recent Clin Trials 2006, 1(1):43-51. Review, 10.2174/157488706775246148, 18393779.
29. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95(2):190-8. 10.3171/jns.2001.95.2.0190, 11780887.
30. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS. Chang S; Glioma Outcomes Investigators: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003, 99(3):467-73. 10.3171/jns.2003.99.3.0467, 12959431.
31. Hentschel SJ, Sawaya R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 2003, 10(2):109-14. Review.
32. Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987, 21(2):201-6. 10.1227/00006123-198708000-00012, 2821446.
33. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009, 91(1):69-81. Epub 2008 Sep 23, 10.1007/s11060-008-9685-3, 3022437, 18810326.
34. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004, 100(1):41-6. 10.3171/jns.2004.100.1.0041, 14743910.
35. Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 1999, 52(4):371-9. 10.1016/S0090-3019(99)00103-2, 10555843.
36. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC, Hummel S, Scharnhorst J, Krohn KA, Spence AM. Volumetric analysis of 18 F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002, 43(12):1667-73.
37. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, Junck L, Lawrence TS. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res 2006, 66(17):8912-7. 10.1158/0008-5472.CAN-05-4328, 16951209.
38. Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 2011, 99(2):218-24. Epub 2011 Apr 16, 10.1016/j.radonc.2011.03.006, 21497925.
39. Weber DC, Miller RC, Villà S, Hanssens P, Baumert BG, Castadot P, Varlet P, Abacioglu U, Igdem S, Szutowicz E, Nishioka H, Hofer S, Rutz HP, Ozsahin M, Taghian A, Mirimanoff RO. Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2006, 66(1):179-86. Epub 2006 Jul 11, 10.1016/j.ijrobp.2006.04.035, 16814953.
40. Wang YY, Yang GK, Li SY, Baol XF, Wu CY. Prognostic factors for deep situated malignant gliomas treated with linac radiosurgery. Chin Med Sci J 2004, 19(2):105-10.
41. Kowalczuk A, Macdonald RL, Amidei C, Dohrmann G, Erickson RK, Hekmatpanah J, Krauss S, Krishnasamy S, Masters G, Mullan SF, Mundt AJ, Sweeney P, Vokes EE, Weir BK, Wollman RL. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997, 41(5):1028-36. discussion 1036-8, 10.1097/00006123-199711000-00004, 9361056.
42. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996, 27(1):65-73. 10.1007/BF00146086, 8699228.
43. Xue D, Albright RE. Preoperative anaplastic glioma tumor volume effects on patient survival. J Surg Oncol 1999, 72(4):199-205. 10.1002/(SICI)1096-9098(199912)72:4<199::AID-JSO4>3.0.CO;2-O, 10589034.
44. Burger PC, Heinz ER, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 1988, 68(5):698-704. 10.3171/jns.1988.68.5.0698, 2833587.
45. Segall HD, Destian S, Nelson MD, et al. CT and MR imaging in malignant gliomas. Malignant Cerebral Glioma 1990, 63-77. Park Ridge, IL: American Association of Neurological Surgeons, Apuzzo MLJ.
46. Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 2010, 12(8):822-33. Epub 2010 Feb 23, 10.1093/neuonc/noq017, 2940678, 20179017.
47. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ. Relationship of preoperative metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol 2009, 91(3):337-51. Epub 2008 Nov 15, 10.1007/s11060-008-9719-x, 3022444, 19009235.
48. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 2008, 113(5):1032-42. 10.1002/cncr.23678, 2574798, 18618497.
49. Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004, 17(1):10-20. 10.1002/nbm.858, 15011246.
50. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002, 51(1):2-12. discussion 12-3. Review, 10.1097/00006123-200207000-00002, 12182418.
51. D' Angelo MG, Afanasieva T, Aguzzi A. Angiogenesis in transgenic models of multistep carcinogenesis. J Neurooncol 2000, 50(1-2):89-98. Review.
52. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992, 359:843-845. 10.1038/359843a0, 1279431.
53. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848. 10.1038/359845a0, 1279432.
54. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005, 7:134-153. 10.1215/S1152851704001115, 1871894, 15831232.
55. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010, 116(17):3988. 10.1002/cncr.25256, 20564141.
56. Earnest F, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, Forbes GS, Axley PL. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988, 166(3):823-7.
57. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histologic correlations of computed tomography-and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987, 62(6):450-9.
58. Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP, Nelson SJ. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004, 19(5):546-54. 10.1002/jmri.20039, 15112303.
59. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004, 59(1):126-37. 10.1016/j.ijrobp.2003.08.023, 15093908.
60. Thiele F, Ehmer J, Piroth MD, Eble MJ, Coenen HH, Kaiser HJ, Schaefer WM, Buell U, Boy C. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol 2009, 54(18):5525-39. Epub 2009 Aug, 10.1088/0031-9155/54/18/012, 19717889.
61. Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 2009, 64(3):471-81. discussion 481, 10.1227/01.NEU.0000338949.94496.85, 19240609.
62. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, Coenen HH, Kaiser HJ, Langen KJ, Eble MJ. Prognostic value of early [18 F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011, 80(1):176-84. Epub 2010 Jun 18, 10.1016/j.ijrobp.2010.01.055, 20646863.
63. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2009, 11(6):842-52. Epub, 10.1215/15228517-2009-005, 2802404, 19229057.
64. Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM, Rogers CL, Corn BW. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol 2009, 27(5):733-9. Epub 2008 Dec 29, 10.1200/JCO.2008.18.9035, 2645087, 19114694.
65. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009, 4(4):255-64. Epub 2009 May 29.
66. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009, 15(21):6683-93. Epub 2009 Oct 27, 10.1158/1078-0432.CCR-08-2801, 19861461.